Parkinson's disease has no disease-modifying treatment, and the pesticide rotenone is widely used to reproduce its mitochondrial and oxidative features in rodents. Resveratrol, a plant polyphenol with antioxidant and sirtuin-related activity, has been studied as a neuroprotective candidate in this and related models. This review summarises published work on the rotenone rat model, the pharmacology of resveratrol, and evidence for protection in toxin-based parkinsonism, and it reports no new experimental data. Studies describe preserved dopaminergic neurons, reduced oxidative stress and better motor performance, but doses vary, the model is inconsistent, and resveratrol has poor bioavailability. Translation to patients is unproven, and standardised, well-reported preclinical studies are needed.
No takes yet. Share an insight, caveat, or question.
Prochazka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: